PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 18.73 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Dermira Inc | DERM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.37% | 18.73 | 18.81 | 18.73 | 18.81 | 18.80 | 16:30:04 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 18.70 | 18.74 | 0.04 | 0.21% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,487 | 1,119,810 | $ 18.75 | $ 21,001,261 | 3,707,083 | 5.25 - 25.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:30:26 | 50 | $ 18.70 | USD |
Dermira Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 1.02B | 54.70M | $ -221.54M | -5.27 | - | 54.33M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Dermira News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/27/2020 | 13:29 | Edgar (US Regulatory) | Schedule 13g |
| 1/22/2020 | 07:15 | Edgar (US Regulatory) | Statement of Ownership: Solicitation (sc 14d9) |
| 1/22/2020 | 07:05 | Edgar (US Regulatory) | Tender Offer Statement by Third Party (sc To-t) |
| 1/15/2020 | 11:16 | PR Newswire (US) | Moore Kuehn, PLLC Encourages PRMW, DERM, CBB, and HABT.. |
| 1/13/2020 | 11:39 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 1/10/2020 | 16:53 | Edgar (US Regulatory) | Written Communication by the Subject Company Relating to a.. |
| 1/10/2020 | 15:23 | PR Newswire (US) | SHAREHOLDER ALERT: WeissLaw LLP Investigates Dermira, Inc. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DERM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 18.84 | 19.0998 | 18.68 | 18.78 | 5,469,854 | -0.11 | -0.58% |
| 1 Month | 15.39 | 25.99 | 12.50 | 18.65 | 4,799,784 | 3.34 | 21.7% |
| 3 Months | 6.60 | 25.99 | 6.30 | 15.47 | 2,560,612 | 12.13 | 183.79% |
| 6 Months | 8.50 | 25.99 | 5.25 | 12.94 | 1,640,893 | 10.23 | 120.35% |
| 1 Year | 6.44 | 25.99 | 5.25 | 12.26 | 1,515,727 | 12.29 | 190.84% |
| 3 Years | 28.08 | 38.75 | 5.25 | 14.15 | 973,759 | -9.35 | -33.3% |
| 5 Years | 16.93 | 38.75 | 5.25 | 15.58 | 650,605 | 1.80 | 10.63% |
Dermira Description
| Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. |
